Process Development and Large-scale GMP Production for Lentiviral Vectors

[WEBINAR] Case Study: Process Development and Large-scale GMP Production for Lentiviral Vectors

How efficient are your lentiviral vector large-scale production and purification processes?
MolMed offers in-house proprietary processes for lentiviral (LV) vector production at large scale. As the evolution of the well-established GMP 48L CF process MolMed is developing a robust and scalable process for the industrial-scale production of both LV vectors for use in gene-modified cell therapy using a scalable platform that includes the iCELLis bioreactor vector production and a downstream purification platform that includes chromatography and TFF steps.

In this session, you are presented with a wealth of productivity and quality data obtained with the CF process and the development and optimisation of the LV production process in a bioreactor.
Phacilitate webinar with Beckman Coulter - managing cell culture
During this webinar, you will learn:
  • How to perform an efficient LV vector large-scale production and purification processes
  • Process development and large-scale production process using the iCELLis platform
  • How to design an industrial scale viral vector production from bulk production to final filled product

DETAILS
You can get on-demand access here.


SPEAKERS
Prof Francesco Dazzi, KCL, Phacilitate webinar

Luca Alberici, MBA, CBO, MolMed S.p.a.






Steven Thompson, Sexton Biotechnologies Phacilitate webinar
Margherita Neri, Up-stream Process Development Manager, MolMed S.p.a.






Francesca Bellintani, Down-stream Process Development Manager, MolMed S.p.a.